:: Volume 4, Issue 2 (Int Biol Biomed J 2018) ::
IBBJ 2018, 4(2): 82-88 Back to browse issues page
In silico Studies for Comparison of FliCs from Salmonella typhimorium, Pseudomonas aeruginosa, and Escherichia coli and their Implication as an Adjuvant
Zakaria Bameri1 , Mohammad Reza Asadi Karam1 , Mehri Habibi1 , Mana Oloomi1 , Parastoo Ehsani1 , Saeid Bouzari * 2
1- Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran
2- Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran , saeidbouzarii@yahoo.com
Abstract:   (7677 Views)
An increasing number of studies have demonstrated the effectiveness of flagellin (FliC) as an adjuvant. In this study, FliC(s) from Salmonella enterica serovar Typhimurium, Pseudomonas aeruginosa, and Escherichia coli were compared. In silico studies were designed to determine physicochemical parameters of FliC from different bacteria. The fliC gene corresponding to best model was amplified, cloned and expressed into pET28a vector. Bioactivity of the protein was determined by measurement of the interleukin 8 in cell culture after interaction of FliC with TLR-5. According to in silico studies, FliC of S. typhimorium has a higher quality of physiochemical properties, and more affinity to TLR-5 than the other FliCs. SDS-PAGE showed an approximately 54 kDa band, and Western blot confirmed the presence of recombinant protein. IL-8 was expressed significantly in cell culture under S. typhimorium FliC induction. Considering side effects, and costs of conventional adjuvants, FliC can be introduced as a potent natural adjuvant in future studies. In silico studies can save time and cost, and screen potent proteins.
Keywords: Salmonella typhimurium, FliC, adjuvant
Full-Text [PDF 776 kb]   (2632 Downloads)    
Type of Study: Original Article | Subject: Medical Biotechnology
Received: 2017/10/22 | Accepted: 2017/11/21 | Published: 2017/12/17


XML     Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 4, Issue 2 (Int Biol Biomed J 2018) Back to browse issues page